Episode #102: Hybrid Peptides, Peptide Research Updates, and Bioregulators

About this video

Niddam and Jean-Francois Tremblay survey several research topics: a hybrid combining thymosin alpha-1 with LL-37, thymosin beta-4 and its separate fragments, a senolytic-related compound, and synthetic bioregulator dosing debates. Tremblay argues the hybrid was designed to reduce unwanted cytotoxic effects while keeping immune activity, and that individual beta-4 fragments may offer more targeted effects than the full peptide. They stress caution with senolytic approaches because, in Tremblay’s view, immune training and incomplete clearance matter. The episode carries a paid promotion for a peptide vendor. Most discussion is mechanistic and experiential, with the speakers acknowledging limited research on the newer hybrid.

Key takeaways

• Hybrid peptides are attempts to balance efficacy against unwanted effects, not proven upgrades
• Fragments of a larger peptide can have distinct, narrower actions than the parent compound
• Senolytic strategies require caution when clearance cannot be measured, Tremblay argues
• Lower-dose arguments for bioregulators rest on source-literature interpretation, not new trials
• New market compounds often arrive well ahead of human evidence

Episode details: published June 28, 2022 · 3.1K views · 56:44 long. Summary written by Self Growth Videos from the episode itself. The longevity and peptide concepts described are Nathalie Niddam’s or her guests’, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Niddam promotes peptide products through affiliate arrangements with peptide vendors, a commercial conflict; Self Growth Videos reproduces none of her codes.

← Previous: Episode #100: Top Biohacking and Peptide Picks From Nat Niddam After 100 Episodes · Next: Episode #103: Safe Sunscreen, Circadian Rhythm, and Do We Actually Age with Sun? →

All Nathalie Niddam videos · Nathalie Niddam profile · Nathalie Niddam (official site)